Phathom Pharmaceuticals
Menu Button
Search
Close

Investors & Media

Corporate Profile

Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases and disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB).

We released topline results from three pivotal Phase 3 clinical trials for the treatment of H. pylori infection, the treatment of erosive GERD, and the treatment of symptomatic non-erosive GERD.

Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

September 26, 2023

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies New drug application (NDA) seeks U.S....
LEARN MORE

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

September 5, 2023

FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the...
LEARN MORE

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

August 21, 2023

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for Erosive...
LEARN MORE